Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Alto Neuroscience, Inc.
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
May 09, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
April 23, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
April 03, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
March 21, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
March 11, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
March 07, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 06, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
February 01, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Data from Presentations at the 62nd Annual Meeting of the American College of Neuropsychopharmacology
December 07, 2023
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-300 in Major Depressive Disorder
December 04, 2023
From
Alto Neuroscience, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.